Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 90
- Registration Number
- NCT03647839
- Locations
- 🇦🇺
Eastern Health, Box Hill, Victoria, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺Ballarat Health Service, Ballarat, Victoria, Australia
A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 250
- Registration Number
- NCT02773524
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Bon Secours Cancer Institute, Midlothian, Virginia, United States
🇦🇺Canberra Hospital, Canberra, Australian Capital Territory, Australia
A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
- Conditions
- Gastrointestinal Stromal Tumour
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 78
- Registration Number
- NCT02365441
- Locations
- 🇦🇺
Prince of Wales Hospital, Sydney, New South Wales, Australia
🇦🇺Flinders Medical Centre, Adelaide, South Australia, Australia
🇦🇺Sir Charles Gairdner, Perth, Western Australia, Australia
Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study
- Conditions
- Midgut Neuroendocrine TumoursPancreatic Neuroendocrine Tumours
- Interventions
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 75
- Registration Number
- NCT02358356
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
🇦🇺Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇦🇺Royal North Shore Hospital, St Leonards, New South Wales, Australia
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
- Conditions
- Gastric Cancer
- Interventions
- Radiation: Preoperative chemoradiotherapyProcedure: Gastric resection
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 574
- Registration Number
- NCT01924819
- Locations
- 🇨🇦
UHN - Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
🇨🇦Hospital Notre-Dame, Montreal, Quebec, Canada
The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2007-08-22
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 333
- Registration Number
- NCT00294359
- Locations
- 🇦🇺
Nepean Hospital, Sydney, New South Wales, Australia
🇦🇺North Shore Private Hospital, Sydney, New South Wales, Australia
🇦🇺Prince of Wales Hospital, Sydney, New South Wales, Australia